MedTrace Logo

The Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates

NCT03700957 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-10-09

No results posted yet for this study

Summary

The study will assess the efficacy of Docosahexaenoic Acid in reducing the incidence of necrotizing enterocolitis in premature infants.

Conditions

  • Necrotizing Enterocolitis

Interventions

DIETARY_SUPPLEMENT

Docosahexaenoic Acid

100 milligrams of Docosahexaenoic Acid

OTHER

placebo

placebo

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Dina Abou El Fadl, Msc. · Future University in Egypt

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
3 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-31
Primary Completion
2019-06-30
Completion
2019-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03700957 on ClinicalTrials.gov